Start › Rak pęcherza moczowego › Massachusetts › Boston
Badania kliniczne dla Rak pęcherza moczowego w mieście Boston, MA
26 badań dla Rak pęcherza moczowego szuka uczestników w ośrodkach w mieście Boston i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekrutacjaFaza 1
- Massachusetts General Hospital, Boston
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
RekrutacjaFaza 3
- Brigham and Women's Hospital, Boston
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
RekrutacjaFaza 2
- Massachusetts General Hospital Cancer Center, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RekrutacjaFaza 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RekrutacjaFaza 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
RekrutacjaFaza 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Patient-Centered Surgical Prehabilitation
RekrutacjaZapraszamy zdrowych ochotników
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
RekrutacjaFaza 3
- Dana Farber Cancer Institute ( Site 0783), Boston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RekrutacjaFaza 3
- Massachusetts General Hospital, Boston
Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy
Rekrutacja
- Dana Farber Cancer Institute, Boston
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
RekrutacjaFaza 1
- Dana-Farber Cancer Institute, Boston
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
RekrutacjaFaza 2
- Brigham and Women's Hospital, Boston
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
RekrutacjaFaza 2
- Brigham and Women's Hospital, Boston
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RekrutacjaFaza 1
- Massachusetts General Hospital, Boston
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
RekrutacjaFaza 3
- Massachusetts General Hospital Cancer Center, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RekrutacjaFaza 1/2
- Massachusetts General Hospital Cancer Center, Boston
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
RekrutacjaFaza 1/2
- Brigham and Women's Hospital, Boston
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
RekrutacjaFaza 2/3
- Local Institution - 0195, Boston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RekrutacjaFaza 2
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
RekrutacjaFaza 3
- Research Site, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RekrutacjaFaza 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- i 2 więcej
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
RekrutacjaBadanie obserwacyjne
- Dana-Farber Cancer Institute, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Rekrutacja
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Sacituzumab Govitecan Plus EV in Metastatic UC
RekrutacjaFaza 1/2
- Dana Farber Cancer Institute, Boston
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
Rekrutacja
- Harvard School of Medicine/Massachusetts General Hospital (MGH), Boston
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
RekrutacjaFaza 3
- Brigham and Women's Hospital, Boston
Badania dla Rak pęcherza moczowego w innych miastach
- New York City, NY35 badań
- Nashville, TN31 badań
- Houston, TX31 badań
- Dallas, TX27 badań
- Washington, DC26 badań
- Los Angeles, CA24 badań
- Baltimore, MD24 badań
- St. Louis, MO22 badań
- Philadelphia, PA21 badań
- Seattle, WA21 badań
- Edison, NJ21 badań
- Chicago, IL21 badań
Inne badania w mieście Boston
- Rak piersi111 badań
- Niedrobnokomórkowy rak płuca90 badań
- Nowotwory (wszystkie typy)86 badań
- Rak jelita grubego i odbytnicy63 badań
- Nowotwór przerzutowy63 badań
- Rak płuc62 badań
- Rak jajnika61 badań
- Rak prostaty59 badań
- Depresja52 badań
- Rak endometrium50 badań
- Niewydolność serca44 badań
- Ostra białaczka szpikowa44 badań
Źródło: ClinicalTrials.gov, dane pobrane 5 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.